Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HPV (human papilloma virus) predicts cervical radiotherapy efficacy:

This article was originally published in Clinica

Executive Summary

Testing for the human papilloma virus (HPV) in women with advanced cervical cancer could help predict how well the patients will respond to radiotherapy used to cure the disease, according to a Swiss study. Dr Katja Lindel and colleagues from the University Berne Hospital report that HPV is an independent prognostic parameter for clinical outcome and a predictive factor for radiation response. Results from their study of 40 patients treated with radiotherapy showed that HPV-positive women had slightly higher rates of overall survival and were significantly more likely to have their cancer go into remission than HPV-negative women, 67% versus 33%, respectively.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts